Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced…
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing…
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight…
Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in…
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…
Strategic Hires Underscore Momentum as Company Expands Global Commercialization of Long-Range Wireless Power TEL AVIV, Israel, Aug. 7, 2025 /PRNewswire/…
Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in…
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of…
– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase…
PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB…